

10th Annual CUA-CUOG Multidisciplinary GU Cancers Meeting 2025

CUOG

Agenda

Sunday, June 28, 2025 Westin Ottawa | Governor General 1-2 | Level 4 Ottawa, Ont.

| 08:00 | Welcome & Introduction: Frédéric Pouliot |
|-------------------------------------|---|
| Evolving B | iomarkers Moderator: Maria Di Jiang |
| 08:05 - 08:20 | State-of-the-Art: Peri-operative ctDNA to guide management of muscle-invasive bladder cancer Marie-Pier St. Laurent |
| 08:20 - 08:35 | State-of-the-Art: Molecular imaging and theranostics in renal cell carcinoma Frédéric Pouliot |
| 08:35 - 08:50 | State-of-the-Art: Biomarkers of response to androgen deprivation therapy in mCSPC Tanya Dorff |
| | |
| Shifting Sa | nds – Debates in Current Practice Moderator: Melissa Huynh |
| Shifting Sa 08:50 - 09:15 | nds – Debates in Current Practice Moderator: Melissa Huynh BCG plus immune checkpoint blockade is the new standard first-line treatment for high-risk non-muscle invasive bladder cancer Pro: Brant Inman / Con: Stephen Boorjian |
| | BCG plus immune checkpoint blockade is the new standard first-line treatment for high-risk non-muscle invasive bladder cancer |
| 08:50 - 09:15 | BCG plus immune checkpoint blockade is the new standard first-line treatment for high-risk non-muscle invasive bladder cancer Pro: Brant Inman / Con: Stephen Boorjian Stereotactic radiation should be offered as a treatment option to patients with a small renal mass |

- 10:05 10:20 State-of-the-Art: The evolving role of PET imaging and lymphoscintigraphy for penile cancer management Michele Lodde
- 10:20 10:35 State-of-the-Art: Update on HIF inhibitors in RCC Aly-Khan Lalani
- 10:35 10:50 State-of-the-Art: A New Frontier: Bi-specific T-cell engagers (BITES) Daniel Khalaf
- 10:50 11:00 Closing Remarks: Frédéric Pouliot